Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. NewAmsterdam Pharma Company NV shares valued at $199,500 were sold by Kastelein Johannes Jacob Piete on Jan 05 ’26. At $33.25 per share, Kastelein Johannes Jacob Piete sold 6,000 shares. The insider’s holdings dropped to 73,481 shares worth approximately $2.6 million following the completion of this transaction.
Also, Kooij Louise Frederika sold 2,647 shares, netting a total of over 88,013 in proceeds. Following the sale of shares at $33.25 each, the insider now holds 12,353 shares.
Before that, Somaiya Mayur Ian had sold 5,118 shares from its account. In a trade valued at $170,174, the Chief Financial Officer traded NewAmsterdam Pharma Company NV shares for $33.25 each. Upon closing the transaction, the insider’s holdings decreased to 5,118 shares, worth approximately $1.17 million.
Analysts at Wells Fargo started covering the stock with ‘”an Overweight”‘ outlook in a report released in late August. As of July 17, 2025, Goldman has initiated its “Neutral” rating for NAMS. Earlier on June 17, 2025, Citigroup initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
On last trading session, NewAmsterdam Pharma Company NV [NASDAQ: NAMS] rose 4.20% to $35.45. The stock’s lowest price that day was $34.34, but it reached a high of $35.875 in the same session. During the last five days, there has been a surge of approximately 2.04%. Over the course of the year, NewAmsterdam Pharma Company NV shares have jumped approximately 36.66%. Shares of the company reached a 52-week high of $35.88 on 01/07/26 and a 52-week low of $32.67 on 01/05/26.
Support And Resistance Levels for NewAmsterdam Pharma Company NV (NAMS)
According to the 24-hour chart, there is a support level at 34.57, which, if violated, would cause prices to drop to 33.69. In the upper region, resistance lies at 36.10. The next price resistance is at 36.76. RSI (Relative Strength Index) is 49.57 on the 14-day chart, showing neutral technical sentiment.
Is NewAmsterdam Pharma Company NV subject to short interest?
Stocks of NewAmsterdam Pharma Company NV saw a sharp steep in short interest on 2025-12-15 dropping by -0.56 million shares to 6.26 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 6.82 million shares. A decline of -8.93% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.69 of the overall float, the days-to-cover ratio (short ratio) decline to 5.69.
Which companies own the most shares of NewAmsterdam Pharma Company NV (NAMS)?
In terms of NewAmsterdam Pharma Company NV share price expectations, FactSet research, analysts set an average price target of 48.5 in the next 12 months, up nearly 42.56% from the previous closing price of $34.02. Analysts anticipate NewAmsterdam Pharma Company NV stock to reach 55 by 2026, with the lowest price target being 37. In spite of this, 1 analysts ranked NewAmsterdam Pharma Company NV stock as Buy at the end of 2026. On June 10, 2025, Stifel assigned a price target of “a Buy” to the stock and initiated coverage with a $44.
